Janux Therapeutics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average and near the bottom of the universe on momentum.
- Signal has read STRONG SELL for 2 weeks.
- Its last 3 Sell calls were followed by a 20% average decline over the next quarter.
- Recent price momentum is -53.2% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 8.7% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D-
How much profit the business keeps from each dollar of sales and capital.
| Operating margin | -1,576.7% | Better than 2% |
| Net margin | -1,136.3% | Better than 2% |
| Return on equity | -11.5% | Better than 19% |
| Return on invested capital | -15.6% | Better than 15% |
Momentum D-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -42.0% | Better than 9% |
| 6-month return | -30.6% | Better than 18% |
| 12-month return (ex latest month) | -42.2% | Better than 5% |
| Distance below 52-week high | 71.5% | Better than 5% |
Financial Health A-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 39.0x | Better than 99% |
| Debt to assets | 2.2% | Better than 87% |
| Interest coverage | -31.9x | Better than 9% |
Analyst View A-
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 75.0% | Better than 51% |
| Upside to average target | 205.6% | Better than 95% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 10.29
- Open
- 10.11
- Day range
- 10.05 - 10.54
- Avg price
- 10.21
- Volume
- 1.11M
- Turnover
- 11.38M
- Turnover ratei
- 2.45%
- Volume ratioi
- 1.44
- Amplitudei
- 4.76%
- 52-week rangei
- 10.05 - 35.34
Valuation
- P/Ei
- -5.51
- P/E (TTM)i
- -6.34
- P/Bi
- 0.68
- EPSi
- -1.83
- Book value / shi
- 14.90
- Net profit
- -111.97M
- Net assets
- 911.63M
Share structure
- Market cap
- 616.73M
- Float capi
- 459.17M
- Shares out
- 61.18M
- Float sharesi
- 45.55M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2021-06-11
71.5% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-1.40M net over the window
Short interest
- Shares short
- 5.33M
- % of floati
- 8.72%
- Days to coveri
- 7.98
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Janux Therapeutics (JANX)?
Janux Therapeutics last traded at 10.08. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Janux Therapeutics's market cap?
About 616.73M.
What is the P/E ratio of Janux Therapeutics?
The trailing twelve-month P/E is -6.34. The Valuation tab shows it against the stock's own five-year range.
Does Janux Therapeutics pay a dividend?
Janux Therapeutics does not currently pay a regular dividend.
Is Janux Therapeutics a buy according to analysts?
The consensus of 12 analysts is a Buy rating, with an average 12-month price target of 30.80, which implies 205.6% upside from the current price. This is not investment advice.
What is Janux Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Janux Therapeutics a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.
Quote time 2026-11-20 20:02:21 · For reference only, not investment advice and not tailored to your situation.
Janux Therapeutics discussion 0 comments